Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer

Fig. 1

Low Par3 expression is associated with good overall survival and prognosis. We analyzed the duration of response; overall survival (OS), and progression-free survival (PFS) using resected samples from 50 ovarian cancer patients (22 clear-cell carcinomas, 16 serous adenocarcinomas, and 12 endometrioid carcinomas). All patients received primary surgery, including hysterectomy, bilateral salpingo-oophorectomy, and omentectomy, together with systematic lymphadenectomy (when mass reduction was completely or optimally achieved). The patients with stage IC–IV received six to eight cycles of adjuvant chemotherapy (paclitaxel and carboplatin). There were three patients with stage Ia who did not receive any chemotherapy. In this study, the patients with neoadjuvant chemotherapy were excluded. Tissue sections with a high proportion of carcinoma cells (>50%) were reviewed by a pathologist and selected for DNA and total RNA extraction. Kaplan-Meier plots for overall survival (a) and progression free survival (b) were plotted and analysis was performed using the log-rank test. Low Par3 expression was significantly associated with good prognosis (OS: P = 0.002; PFS: P = 0.0033)

Back to article page